Treat an equity offer as a risk-adjusted asset, not a bonus stacked on top of your normal rate. Price it using the startup's stage, vesting terms, dilution trajectory, and realistic exit odds — then set your cash-to-equity split based on your own runway and your genuine conviction in the thesis, not the founder's optimism.
Quick answer: Most startup equity resolves to zero, so discount it hard before you compare it to cash. Set a cash floor that covers your fixed costs, then size any equity component to your runway and how strongly your own diligence — not the founder's pitch — supports the startup's thesis.
Equity Is a Risk-Adjusted Asset, Not Free Upside
A startup advisory grant is compensation with a payout probability attached, not upside layered on top of a normal rate. Most equity grants are worth nothing at exit. Pricing one honestly means multiplying the paper value by realistic odds of a liquidity event, then comparing that number to the cash you're giving up.
Founders reach for equity for a straightforward reason: it's cheap for them and expensive for you. It preserves cash, and it's framed as "skin in the game" — a signal you believe in the mission. Both can be true and the deal can still be underpriced.
Three questions cut through most equity pitches fast:
- What percentage, fully diluted, am I actually being offered — not percentage of the current cap table?
- What has to happen, concretely, for this equity to ever convert to cash?
- What am I giving up in cash rate to accept it?
If you already work a defined vertical niche as a fractional PM, you'll see this pitch constantly — seed-stage founders in your niche often assume advisory equity is simply how PM help gets paid for at their stage. It isn't a universal norm; it's a negotiating opener.
Before you evaluate any single offer, it helps to know where equity-based advisory work fits into the broader economics of the role. The complete guide to fractional PM work is a useful baseline for how rate, scope, and equity typically interact across a portfolio of clients.
The Valuation Lens: Five Inputs That Actually Set the Price
What your shares are worth depends on five levers: company stage, the vesting schedule and cliff, how much future rounds will dilute you, the strike price and exercise mechanics, and — the one that dominates everything else — the realistic odds of any exit at all. Move any one lever and the risk-adjusted value swings by an order of magnitude.
Stage Sets the Base Rate
Earlier-stage companies grant more equity because there's less proof anything works yet — the percentage is compensation for uncertainty, not generosity. As a company raises subsequent rounds and derisks, advisor grants shrink because the same percentage now represents far more absolute dollars if things go well.
Vesting and the Cliff Aren't Fine Print
A standard startup vesting schedule — four years, with a one-year cliff — is the template baked into most NVCA model financing documents, and advisory grants usually borrow a shorter version of it. If you leave or the engagement ends before the cliff, you get nothing, regardless of the percentage on the term sheet.
Dilution Compounds Every Round After Yours
Your percentage on day one is not your percentage at exit. Every subsequent priced round dilutes existing holders, including advisors, unless you negotiate anti-dilution protection you almost never get at this scale. A 0.3% grant today can easily be 0.1% or less by the time there's a liquidity event.
| Stage | Typical advisor equity range* | Standard vesting | Directional odds of any payout |
|---|---|---|---|
| Pre-seed / idea stage | 0.5% – 1%+ | 4yr, 1yr cliff | Lowest — most fail before product-market fit |
| Seed | 0.25% – 0.5% | 4yr, 1yr cliff (or 2yr for advisors) | Low, but improving with traction evidence |
| Series A | 0.1% – 0.25% | Shorter, often 2-3yr | Moderate — company has revenue or clear PMF signal |
| Series B+ | 0.02% – 0.1% | Shorter still | Higher, but upside is capped by prior dilution |
*Directional ranges drawn from commonly cited advisor-equity benchmarks (Fred Wilson's widely referenced AVC post on advisor shares, and equity-management platform Carta's compensation benchmarking data) — actual offers vary by company, role scope, and negotiating leverage.
The table is the fast version. The slow version is that a 1% grant at pre-seed and a 0.05% grant at Series B can carry a similar realistic expected value, because the earlier grant is diluted and derisked far more between now and any exit.
What Realistic Exit Odds Actually Look Like
Most venture-backed startups do not return investor capital, let alone deliver a life-changing advisor payout — a small minority of deals drive nearly all the returns in the entire asset class. Treat any single startup's odds as closer to a long-shot bet than a probable outcome, and price your equity accordingly.
The data backs this up directionally, not precisely. Correlation Ventures, in a widely cited analysis of over 21,000 venture financings, found that roughly two-thirds of financings returned less than the capital invested, while only a small sliver — in the single digits, percentage-wise — produced the outsized returns (10x or more) that drive the asset class's aggregate performance. Cambridge Associates' venture capital benchmark data tell a similar story from the limited-partner side: fund-level returns are dominated by a handful of outlier positions, not the median deal in the portfolio.
Base rates for the underlying businesses aren't much friendlier. The U.S. Bureau of Labor Statistics' Business Employment Dynamics data has repeatedly shown that roughly half of new establishments survive to their fifth year — and venture-backed startups skew toward more capital-intensive, higher-burn models than the average small business, not less risky ones.
None of this means equity is a bad bet. It means you should never price it as if the median outcome resembles the founder's pitch deck.
Conviction Is the Variable You Actually Control
You can't change base rates, but you can change how much better-than-average your specific bet is — through real diligence, not vibes. Two questions matter more than the founder's confidence: is there evidence of a validated core problem, and is there a customer journey that shows people actually adopting and sticking with the product.
If you're doing this diligence seriously, it's worth applying the same rigor you'd bring to a paying client's roadmap. Running the startup's stated problem through a jobs-to-be-done framework tells you whether the "job" customers are hiring the product for is real and underserved, or assumed. Mapping a customer journey tells you whether early users are actually progressing toward habitual use, or churning quietly while the founder talks about "engagement."
A thesis with evidence behind it deserves a bigger equity allocation than a thesis that's just a founder's confidence. That distinction is the entire point of conviction-weighting your cash-to-equity split, covered next.
The Cash-to-Equity Decision Rule: Size the Trade to Runway and Conviction
Your cash-to-equity split should be a function of two things you actually control: how many months your own runway can absorb zero return from this engagement, and how strong your evidence-based conviction is in the startup's specific thesis. Founder charisma is not an input.
Start with a non-negotiable cash floor. This is the minimum monthly cash that covers your fixed costs — rent, insurance, taxes, the baseline that keeps your practice solvent regardless of any single client's outcome. Nothing below that floor should ever be equity, no matter how good the pitch sounds.
| Your runway | Your conviction in the thesis | Recommended split (cash / equity-equivalent value) |
|---|---|---|
| Under 6 months | Any level | 80% – 100% cash; equity only as a small upside kicker |
| 6–12 months | Low-to-moderate (pitch-only, no evidence) | 60% – 75% cash / 25% – 40% equity |
| 6–12 months | High (validated JTBD + journey evidence, real traction) | 50% cash / 50% equity |
| 12+ months | High, with real diligence behind it | Up to 60% – 70% equity, capped by your own floor |
The rule is deliberately conservative on the low end: a fractional PM with thin runway who takes an equity-heavy deal is making a bet with their own solvency, not just their time. If you're already juggling several clients to fill a book of work, the accounting gets messier before it gets more lucrative — worth reading alongside the tradeoffs in managing context switching across multiple clients, since an equity-heavy engagement usually demands more sustained attention than a pure cash retainer, not less.
Worked Example: Pricing a 0.3% Advisory Grant at Seed Stage
Here's how the math actually runs, using a hypothetical (not a real company) to keep the mechanics concrete. A seed-stage startup — $2M raised, roughly $10M post-money — offers a fractional PM 0.3% in equity, vesting monthly over two years with a six-month cliff, in place of a cash retainer for 12 hours a week.
Step one: price the paper value. 0.3% of a $10M post-money valuation is $30,000 in current, undiluted paper value — before any future dilution reduces that percentage, and before you account for whether the company ever reaches a liquidity event at all.
Step two: apply a realistic odds haircut. Using the directional base rates above — a startup at this stage has a low, single-to-low-double-digit percentage chance of a meaningful exit, and even a successful exit will have diluted the 0.3% down further — a defensible risk-adjusted expected value lands well under the $30,000 paper number, plausibly in the low thousands once cliff risk and dilution are both priced in.
Step three: compare to the cash you're forgoing. If a comparable cash retainer for 12 hours a week over the same period would run in the tens of thousands of dollars, the risk-adjusted equity value likely doesn't clear that bar on its own — which is exactly why a blended offer, not pure equity, is the realistic ask.
- Counter with a cash floor (even a below-market one) plus the equity, rather than accepting equity-only.
- Ask whether the grant is on a fully diluted basis or the current cap table — the same 0.3% can mean meaningfully different things.
- Confirm the vesting cliff and what happens to unvested shares if either side ends the engagement early.
Structuring the Deal So You Don't Regret It
A fair equity deal isn't just about the percentage — it's about the mechanics that determine whether that percentage ever becomes real value, and what happens if the engagement or the company changes shape. Get these in writing before you start work, not after.
- Set a cash floor first. Negotiate the minimum cash component before discussing equity at all, so the equity conversation is about upside, not survival.
- Confirm standard vesting with a real cliff. A
cliffof at least three to six months protects the company from a fast exit; a longer one without proportional upside mostly protects the company at your expense. - Ask about acceleration.
Double-trigger acceleration(vesting speeds up if the company is acquired and your engagement ends) is standard for employees and reasonable to request for advisors doing substantial work. - Get exercise terms and expiration windows in writing, especially if you're granted options rather than restricted stock — a short post-termination exercise window can quietly void vested equity you already earned.
- Define scope before you define price. Locking in what you'll actually deliver in the first weeks — the approach covered in scoping a PM engagement for week-one value — prevents the classic failure mode where equity was priced for light advisory input but the actual ask quietly grows into a part-time operating role.
- Reserve the right to renegotiate at each subsequent round. Dilution is normal; being silently diluted without any renegotiation conversation is not something you have to accept.
Documenting the Thesis Behind the Bet
Every equity decision rests on a thesis: this founder, this market, this evidence of traction, justify shares over cash right now. That thesis is easy to remember accurately in month one and easy to misremember — usually more favorably than reality — by month twelve.
Writing the thesis down when you make the bet, and revisiting it against what actually happens, is the only way to know if your conviction was well-founded or just optimism with a spreadsheet attached. Prodinja's Journals feature is built for exactly this kind of running record — a place to log the specific assumptions behind taking equity over cash, so you can come back later and check whether the startup is actually tracking against the thesis that justified the trade, rather than relying on memory.
Key Takeaways
- Price equity as a probability-weighted asset, not a bonus — most grants convert to nothing, and the honest comparison is expected value against cash, not paper value against cash.
- Stage, vesting, dilution, and exercise mechanics all move the real number — a 0.3% grant at two different companies can carry wildly different risk-adjusted value.
- Realistic exit odds are grim on average, per directional data from
Correlation VenturesandCambridge Associates— treat any single startup as a long shot, not a likely win. - Set a non-negotiable cash floor covering your fixed costs before any equity conversation begins; never let equity substitute for solvency.
- Size the cash-to-equity split to your runway and your evidence-based conviction, using real diligence — validated jobs-to-be-done and journey evidence — not founder enthusiasm.
- Vesting cliffs, acceleration, and exercise windows determine whether a percentage ever becomes real money — negotiate the mechanics, not just the headline number.
- Write down the thesis behind the bet when you make it, and revisit it deliberately rather than trusting hindsight to grade the decision fairly.
Frequently Asked Questions
Is it worth taking equity instead of cash for fractional PM work?
Only above a cash floor that covers your fixed costs, and only when your own diligence — not the founder's pitch — supports real conviction in the thesis. Below that floor, or without evidence of traction, equity-only work is a high-variance bet with your own solvency, not compensation.
How much equity should a fractional PM advisor expect?
Directionally, advisor grants commonly range from roughly 0.02% to 1%+ depending on stage, with earlier-stage companies granting more percentage to offset higher risk and lower current value. The right number also depends on time commitment and whether cash is part of the package.
What's a fair vesting schedule for startup advisory equity?
A standard structure mirrors employee equity: roughly four-year vesting with at least a six-month to one-year cliff, sometimes shortened for advisors doing lighter, ongoing work. Anything with no cliff at all, or vesting fully at signing, should raise questions about why the company structured it that way.
Should a fractional PM ever work for equity only, with no cash?
Only when runway easily absorbs a zero-return outcome and conviction in the thesis is genuinely high, not just enthusiastic. Even then, a small cash component — even below market rate — is usually worth negotiating, since it signals the company can actually afford to pay something.
How do you value equity from a startup that hasn't priced a round yet?
When the company has only raised on a SAFE or convertible note, there's no priced valuation to anchor the percentage to, which makes the grant harder to price and riskier by default. Ask for the most recent SAFE's valuation cap as a rough anchor, and discount further for the added uncertainty of an unpriced structure.